Number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O

The	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

In	O
the	O
lymphocytes	B-cell_type
with	O
a	O
high	O
GR	B-protein
number	O
,	O
dexamethasone	O
inhibited	O
[	O
3H	O
]	O
-thymidine	O
and	O
[	O
3H	O
]	O
-acetate	O
incorporation	O
into	O
DNA	O
and	O
cholesterol	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	B-cell_type
cells	I-cell_type
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
GR	B-protein
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	O
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O

These	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	B-cell_type
to	O
glucocorticoids	O
changed	O
only	O
with	O
a	O
decrease	O
of	O
GR	B-protein
level	O
.	O

[	O
1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
T-	B-cell_type
and	I-cell_type
B-lymphocyte	I-cell_type
count	O
in	O
patients	O
with	O
glomerulonephritis	O
]	O

Content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	O
D3	O
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole/mg	O
of	O
protein	O
in	O
lymphocytes	B-cell_type
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	O
.	O

In	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
was	O
decreased	O
down	O
to	O
2.04	O
mmole/L	O
and	O
1.09	O
mmole/L	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	O
(	O
PTH	O
)	O
by	O
36	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
lower	O
than	O
1.25	O
ng/ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
cAMP	O
was	O
also	O
decreased	O
in	O
lymphocytes	O
by	O
33	O
%	O
.	O

At	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
decreased	O
1.5-fold	O
in	O
peripheric	O
blood	O
.	O

Treatment	O
with	O
I-hydroxyvitamin	O
D3	O
(	O
1-1.5	O
mg	O
daily	O
,	O
within	O
4	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
and	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	O
affect	O
the	O
PTH	O
content	O
in	O
blood	O
.	O

Concentration	O
of	O
the	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	O
up	O
to	O
39.7	O
fmole/mg	O
after	O
I	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
24.8	O
fmole/mg	O
within	O
4	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
cAMP	O
content	O
was	O
observed	O
in	O
lymphocytes	B-cell_type
.	O

Treatment	O
with	O
1-	O
(	O
OH	O
)	O
D3	O
normalized	O
also	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
content	O
in	O
peripheric	O
blood	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	O
only	O
high	O
content	O
of	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
in	O
lymphocytes	B-cell_type
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O

Tumor	O
and	O
serum	O
beta-2-microglobulin	O
expression	O
in	O
women	O
with	O
breast	O
cancer	O
.	O

To	O
investigate	O
whether	O
the	O
tumor	B-cell_type
expression	O
of	O
beta-2-microglobulin	B-protein
(	O
beta	B-protein
2-M	I-protein
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	O
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	B-cell_type
carcinomas	I-cell_type
from	O
60	O
consecutive	O
female	O
patients	O
.	O

Presence	O
of	O
beta	B-protein
2-M	I-protein
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

No	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O

Likewise	O
,	O
beta	B-protein
2-M	I-protein
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
TNM	O
,	O
(	O
UICC	O
,	O
classification	O
of	O
malignant	B-cell_type
tumors	I-cell_type
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	O
,	O
progesterone	O
,	O
and	O
glucocorticoid	O
receptor	O
levels	O
.	O

However	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	O
tissue	O
.	O

Beta	B-protein
2-M	I-protein
serum	O
levels	O
were	O
determined	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
22	O
of	O
the	O
above	O
women	O
.	O

Although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
T4	O
)	O
primary	O
tumors	O
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-protein
2-M	I-protein
expression	O
in	O
the	O
tumor	O
with	O
serum	O
levels	O
or	O
between	O
serum	B-protein
beta	I-protein
2-M	I-protein
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	O
factors	O
.	O

[	O
Preliminary	O
observation	O
of	O
level	O
free-form	B-protein
E	I-protein
receptor	I-protein
levels	O
in	O
serum	O
of	O
normal	O
childbearing-aged	O
and	O
pregnant	O
women	O
]	O

In	O
137	O
cases	O
of	O
childbearing-aged	O
and	O
pregnant	O
women	O
,	O
free	B-protein
form	I-protein
E	I-protein
receptor	I-protein
levels	O
(	O
sE	B-protein
)	O
in	O
serum	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
level	O
of	O
sE	B-protein
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O

The	O
level	O
remained	O
lower	O
in	O
29	O
PIH	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
3rd	O
trimester	O
range	O
.	O

The	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
T	B-cell_type
cell	I-cell_type
function	O
and	O
pregnancy	O
.	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	O
the	O
regulation	O
of	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
expression	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
,	O
like	O
induction	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	B-protein
B-like	I-protein
enhancer	I-protein
element	I-protein
.	O

Mutation	O
of	O
a	O
kappa	B-DNA
B	I-DNA
core	I-DNA
sequence	I-DNA
identified	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
(	O
-206	O
to	O
-195	O
)	O
partially	O
inhibits	O
both	O
mitogen-	O
and	O
HTLV-I	O
Tax-mediated	O
activation	O
of	O
this	O
transcription	B-protein
unit	I-protein
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	B-protein
cellular	I-protein
factors	I-protein
.	O

These	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
(	O
80	O
to	O
90	O
and	O
50	O
to	O
55	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	O
kappa	B-protein
B	I-protein
enhancer	I-protein
present	O
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

These	O
data	O
suggest	O
that	O
these	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	O
factor-growth	O
factor	O
receptor	O
gene	O
system	O
that	O
controls	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O

Novel	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
neoplasms	I-cell_type
.	O

Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	B-cell_type
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O

Different	O
fragments	O
of	O
unrearranged	B-DNA
human	I-DNA
variable	I-DNA
region	I-DNA
of	O
immunoglobulin	B-DNA
kappa	I-DNA
gene	I-DNA
(	O
V	B-DNA
kappa	I-DNA
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	B-cell_type
neoplasms	I-cell_type
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	B-cell_type
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

[	O
Determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	B-protein
in	O
vitro	O
]	O

A	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
suggested	O
.	O

The	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	B-cell_type
count	O
in	O
a	O
sample	O
(	O
1	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	B-protein
concentration	O
.	O

The	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O

Examinations	O
of	O
70	O
children	O
aged	O
4	O
to	O
15	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
X	O
=	O
6820.1	O
+/-	O
530.0	O
(	O
n	O
=	O
30	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	B-protein
-sensitive	O
glomerulonephritis	O
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
X	O
=	O
1815.2	O
+/-	O
302.8	O
(	O
n	O
=	O
40	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	B-protein
-resistant	O
glomerulonephritis	O
.	O

Dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O

These	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	B-protein
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O

Octamer-binding	B-protein
proteins	I-protein
from	O
B	B-cell_line
or	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
B-cell	B-cell_type
-type	O
specificity	O
of	O
the	O
immunoglobulin	B-protein
(	O
Ig	B-protein
)	O
heavy-chain	O
and	O
light-chain	O
promoters	O
is	O
mediated	O
by	O
an	O
octanucleotide	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
,	O
such	O
as	O
snRNA	O
and	O
histone	O
H2B	O
promoters	O
.	O

Two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
OCTA	B-DNA
element	I-DNA
have	O
been	O
identified	O
.	O

NF-A1	B-protein
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
NF-A2	B-protein
is	O
essentially	O
confined	O
to	O
B	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
NF-A2	B-protein
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
Ig	B-DNA
promoter	I-DNA
and	O
NF-A1	B-protein
mediates	O
the	O
other	O
responses	O
of	O
the	O
OCTA	B-DNA
element	I-DNA
.	O

Extracts	O
of	O
the	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
,	O
contain	O
high	O
